Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update
Key Highlights
- ➤Cash and equivalents $22.0 million at September 30, 2026, versus $28.7 million June 30
- ➤Net loss $64.6 million, including $57.1 million non-cash warrant-liability charge
- ➤Milestone warrant exercise could provide approximately $32.4 million gross proceeds
- ➤IND submission and Phase 1a initiation for AT177 remain planned for first half of 2027
- ➤Azora began Nasdaq trading under ticker AZR on October 29, 2026
Expert Statements
Matt Davidson, President, Co-Founder and Chief Executive Officer of Azora Therapeutics
“With our transition to Nasdaq, Azora is well positioned for success to bring AhR biology to people living with ulcerative colitis.”
Matt Davidson, President, Co-Founder and Chief Executive Officer of Azora Therapeutics
“We are pleased to have recently strengthened our leadership team, appointing Celia Economides as CFO and David Rubenstein, M.D., Ph.D., as Chief Scientist. Dr. Rubenstein led the development and FDA approval of the first AhR agonist.”
Matt Davidson, President, Co-Founder and Chief Executive Officer of Azora Therapeutics
“We have further added to our depth of experience through the appointment of new Board members who bring inflammatory disease, clinical development and company building expertise to Azora.”
Matt Davidson, President, Co-Founder and Chief Executive Officer of Azora Therapeutics
“Our focus now is execution excellence, and we remain on track to submit an IND for AT177 and initiate our Phase 1a trial in the first half of 2027.”
AT177 IND submission and Phase 1a initiation on track for the first half of 2027
LOS ANGELES, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Azora Therapeutics, Inc. (Nasdaq: AZR) (“Azora” or the “Company”), a biopharmaceutical company developing locally acting treatments for serious immune-mediated and inflammatory diseases, today provided a business update and reported its financial results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.